Travere Therapeutics Inc. has announced the issuance of inducement equity grants to 17 new employees, as approved by the Compensation Committee of its Board of Directors on July 10, 2025. These grants consist of restricted stock units (RSUs) covering a total of 121,700 shares of the company's common stock. The RSUs, though issued outside of Travere's 2018 Equity Incentive Plan, adhere to its terms and were granted under Nasdaq Listing Rule 5635(c)(4) as part of the company's strategy to attract new talent. The RSUs will vest over a four-year period, with 25% of the shares vesting on each anniversary of the grant date, contingent upon the continued service of the employees with the company through the vesting dates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。